Therapeutic tyrosine kinase inhibitors for multiple sclerosis
AssigneePrincipia Biopharma Inc.
InventorsDeborah Dukovic, Sana Syed, Timothy J. Turner
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase (“BTK”) inhibitors, for treatment of patients with multiple sclerosis (MS).
Claims122
A method of treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein at least one outcome chosen from the following occurs:
- (a) the risk of confirmed disability progression (CDP) is reduced;
- (b) the total number of new and/or enlarging T2-hyperintense lesions as detected by MRI, defined as the sum of the individual number of new and/or enlarging T2 lesions, are reduced;
- (c) the risk of sustained 20% increase in the timed 25-foot walk (T25-FW) test confirmed over at least 3 months is reduced;
- and
- (d) the chance of confirmed disability improvement (CDI) is improved.
A method of treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein the risk of confirmed disability progression (CDP) is reduced.
A method of reducing the risk of confirmed disability progression (CDP) in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of reducing the total number of new and/or enlarging T2-hyperintense lesions as detected by MRI, in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of reducing the risk of sustained 20% increase in the timed 25-foot walk (T25-FW) test confirmed over at least 3 months, in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of reducing the risk of sustained 20% increase in the 9-hole peg test (9-HPT) confirmed over at least 3 months, in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of improving the chance of confirmed disability improvement (CDI) in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of improving time to onset of confirmed disability progression (CDP) in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of improving time to onset of sustained 20% increase in the timed 25-foot walk (T25-FW) test confirmed over at least 3 months, in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of improving time to onset of sustained 20% increase in the 9-hole peg test (9-HPT) confirmed over at least 3 months, in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of improving time to onset of confirmed disability improvement (CDI) in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of reducing the risk of confirmed disability worsening (CDW) in a patient with a relapsing form of multiple sclerosis (RMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of improving time to onset of confirmed disability worsening (CDW) in a patient with a relapsing form of multiple sclerosis (RMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of improving percent change in brain volume loss (BVL) as detected by brain MRI in a patient with relapsing forms of multiple sclerosis (RMS), comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of treating a patient with primary progressive multiple sclerosis (PPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein at least one outcome chosen from the following occurs:
- (a) the risk of composite confirmed disability progression (cCDP) is reduced, wherein the cCDP comprises progression in at least one of confirmed disability progression (CDP), sustained 20% increase in the timed 25-foot walk (T25-FW) test, and sustained 20% increase in the 9-hole peg test (9-HPT);
- (b) the risk of confirmed disability progression (CDP) is reduced;
- (c) the total number of new and/or enlarging T2-hyperintense lesions as detected by MRI, defined as the sum of the individual number of new and/or enlarging T2 lesions, are reduced;
- (d) the risk of sustained 20% increase in the timed 25-foot walk (T25-FW) test is reduced;
- (e) the risk of sustained 20% increase in the 9-hole peg test (9-HPT) is reduced;
- (f) the chance of confirmed disability improvement (CDI) is improved;
- and
- (g) the percent change in brain volume loss (BVL) as detected by brain MRI is improved.
A method of treating a patient with primary progressive multiple sclerosis (PPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein the risk of confirmed disability progression (CDP) or composite confirmed disability progression (cCDP) is reduced, wherein the cCDP comprises progression in at least one of:
- (a) CDP;
- (b) sustained 20% increase in the timed 25-foot walk (T25-FW) test;
- and
- (c) sustained 20% increase in the 9-hole peg test (9-HPT).
A method of reducing the risk of confirmed disability progression (CDP) or composite confirmed disability progression (cCDP) in a patient with primary progressive multiple sclerosis (PPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein the cCDP comprises progression in at least one of:
- (a) CDP;
- (b) sustained 20% increase in the timed 25-foot walk (T25-FW) test;
- and
- (c) sustained 20% increase in the 9-hole peg test (9-HPT).
A method of improving time to onset of confirmed disability progression (CDP) or composite confirmed disability progression (cCDP) in a patient with primary progressive multiple sclerosis (PPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein the cCDP comprises progression in at least one of:
- (a) CDP;
- (b) sustained 20% increase in the timed 25-foot walk (T25-FW) test;
- and
- (c) sustained 20% increase in the 9-hole peg test (9-HPT).
A method of treating disability accumulation in a patient with multiple sclerosis comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
A method of treating disability progression independent of relapse activity in a patient with multiple sclerosis comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.
The method of any one of claims 80-90, wherein the patient in need thereof has secondary progressive multiple sclerosis (SPMS).
The method of claim 91, wherein the SPMS is non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Dependencies are inferred from the claim text.